BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Isogenica Limited Enters into a License Agreement with Centocor Research And Development, Inc.


9/12/2008 11:55:05 AM

Cambridge, UK, September 12, 2008: Isogenica Ltd today announced that it entered into a license agreement with Centocor Research & Development, Inc. which grants Centocor the non-exclusive right to use Isogenica’s CIS display technology for the discovery of certain therapeutic proteins.

Under the terms of the agreement, Isogenica will receive multi-million pound initial license fees paid over the first three years of the agreement as well as ongoing license maintenance fees and milestone payments associated with the clinical development of products discovered using Isogenica’s technology.

Isogenica's CIS display technology provides a novel and effective means of rapidly identifying peptides, polypeptides and antibodies that bind with high affinity and specificity to any given molecular target. The technology can also be used for enhancing the in vivo performance of peptide therapeutic and diagnostic products.

"We look forward to building a strong and fruitful relationship with Centocor and in assisting them with their therapeutic discovery activities" said Dr. Kevin FitzGerald, Isogenica's CEO. "We believe that CIS display technology provides a powerful new approach for the discovery of compounds for therapeutic and other in vivo applications."



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES